1 / 5

Supplementary Figure 1

A. B. Biochemical Assays ( µ M ) ATR 0.00023 ATM 1.4 DNAPKcs 7.3 mTOR 5.2 PIK3CA >9.1 PI3 b , g , d > 9.1. Cellular Assays (µM ) ATR-pCHK1 S345 0.13 mTOR-pS6K T398 2.1. Supplementary Figure 1. A. mTORi =AZD8055 ( -H2AX E C 50 (+HU) >10 M).

kale
Télécharger la présentation

Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A. B. Biochemical Assays (µM) ATR 0.00023 ATM 1.4 DNAPKcs 7.3 mTOR 5.2 PIK3CA >9.1 PI3b, g, d >9.1 Cellular Assays (µM) ATR-pCHK1 S3450.13 mTOR-pS6K T398 2.1 Supplementary Figure 1

  2. A. mTORi=AZD8055 (-H2AX EC50 (+HU) >10M) DNA-PKcsi=NU7441 (-H2AX EC50 (+HU) >10M) B. ATRi/mTORi (-H2AXEC50 (+HU)=7M) ATMi=KU55933 (-H2AX EC50 (+HU)>10M) C. D. Supplementary Figure 2

  3. A. untreated (0.4%) 1 µM ATRi (2.3%) B. 1 µM gemcitabine + 1 µM ATRi (58.7%) 1 µM gemcitabine (2.2%) H2AX-FITC PI C. 1 µM cytarabine + 1 µM ATRi (42.0%) 1 µM cytarabine (0.6%) 1 µM clofarabine + 1 µM ATRi (47%) D. 1 µM clofarabine (6.4%) E. 5 µM cladribine + 1 µM ATRi (40.4%) 5 µM cladribine (7.3%) Supplementary Figure 3

  4. A. ATRi 2 h ATRi 24 h B. DMSO 0.5 µM 1.0 µM DMSO 0.5 µM 1.0 µM Supplementary Figure 4

  5. B. A. C. D. Supplementary Figure 5

More Related